Cingulate, Inc. (CING)

In the past six months, Cingulate's stock price has experienced high volatility with a significant increase of 71.31%. Key events include reporting Q4 and full-year 2025 financial results with a net loss of $22.4 million, closing a $12 million private placement to support the launch of CTx-1301, the FDA accepting the NDA for CTx-1301 with a PDUFA target action date of May 31, 2026, receiving a Notice of Allowance from the USPTO for a patent application covering its PTR platform, and appointing Bryan Downey as Chief Commercial Officer and Rick Arce as Senior Vice President of Market Access.

Specific detailed demand seasonality for Cingulate, Inc.'s products and services is not publicly available. However, the broader market for ADHD medication sales in the U.S. has shown consistent growth, increasing by approximately 8% annually since 2010, suggesting a generally stable and growing underlying market.

Cingulate, Inc. is a clinical-stage biopharmaceutical company focused on developing pharmaceutical products for ADHD and anxiety using its Precision Timed Release (PTR) drug delivery platform technology. The company's primary focus is on the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. Key product candidates include CTx-1301 (dexmethylphenidate) in Phase 3 clinical trials for ADHD, CTx-1302 (dextroamphetamine) in investigational new drug application development for ADHD, and CTx-2103 (buspirone) in formulation for anxiety.

Cingulate, Inc. is headquartered in Kansas City, Kansas, United States, and its development and commercialization efforts are focused on the U.S. market.

Cingulate's brand reputation is reflected in market sentiment and analyst coverage. MarketBeat scored Cingulate higher than 61% of companies in the medical sector. Analyst ratings show a consensus of "Hold" with an average rating score of 2.33. Positive Phase 3 results for CTx-1301, FDA's acceptance of the NDA, and the allowance of a key patent positively impact reputation, while reported net losses and potential delays in regulatory approval could negatively impact it.

Cingulate, Inc. has a mix of institutional and individual owners. Institutional investors own 41.31% of Cingulate's stock, with major shareholders including Vanguard Group Inc and Kestra Advisory Services LLC. Falcon Creek Capital Advisor LLC reported a significant beneficial ownership of 3,856,766 shares, representing 28.50% of Cingulate's common stock. Individual insiders who own company stock include Peter J Werth, Shane J Schaffer, Jennifer L Callahan, Matthew Brams, and Laurie Myers.